Market capitalization | $10.00k |
Enterprise Value | $-1.40m |
EV/FCF (TTM) EV/FCF | 0.46 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-9.34m |
Free Cash Flow (TTM) Free Cash Flow | $-3.04m |
Cash position | $360.00k |
EPS (TTM) EPS | $-0.32 |
Short interest | 0.25% |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Scopus Biopharma Inc:
1 Analyst has issued a forecast Scopus Biopharma Inc:
Jun '23 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -9.34 -9.34 |
46%
46%
|
EBIT (Operating Income) EBIT | -9.34 -9.34 |
46%
46%
|
Net Profit | -8.70 -8.70 |
45%
45%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of transformational therapeutics targeting serious diseases with unmet medical needs. Its drug candidates comprises of combination of cannabidiol-mediated, opioid-sparing anesthetics, synthesis of cannabinoids, and cannabinoid receptor mediating compounds for the treatment of systemic sclerosis. The company was founded on April 18, 2017 and is headquartered in New York, NY.
Head office | United States |
CEO | Morris Laster |
Founded | 2017 |
Website | www.scopusbiopharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.